XTL Biopharmaceuticals Ltd. (XTLB.TA)
ILA 4.8
(4.35%)
ILA 4.8
(4.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -764 Thousand USD | 99.8% |
| 2022 | -879 Thousand USD | 84.54% |
| 2021 | -1.03 Million USD | -130.05% |
| 2020 | -947 Thousand USD | -304.85% |
| 2019 | - USD | 94.03% |
| 2018 | -792 Thousand USD | -168.5% |
| 2017 | -1.24 Million USD | -94.08% |
| 2016 | -1.71 Million USD | -129.26% |
| 2015 | -2 Million USD | 79.53% |
| 2014 | -1.96 Million USD | -866.84% |
| 2013 | -1.09 Million USD | 94.99% |
| 2012 | -3.79 Million USD | -257.1% |
| 2011 | -1.06 Million USD | 12.29% |
| 2010 | -1.21 Million USD | -146.9% |
| 2009 | 2.58 Million USD | 127.98% |
| 2008 | -18.4 Million USD | 63.86% |
| 2007 | -25.62 Million USD | -60.85% |
| 2006 | -15.8 Million USD | -51.12% |
| 2005 | -12.35 Million USD | 36.12% |
| 2004 | -16.45 Million USD | -207.17% |
| 2003 | 15.35 Million USD | 186.71% |
| 2002 | -17.71 Million USD | -17.11% |
| 2001 | -15.12 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -165 Thousand USD | 438.42% |
| 2023 Q2 | -154 Thousand USD | 35.56% |
| 2023 Q3 | -142 Thousand USD | 7.79% |
| 2023 Q4 | -199.75 USD | 99.86% |
| 2023 Q1 | -239 Thousand USD | -173.54% |
| 2023 FY | - USD | 99.8% |
| 2022 Q4 | 325 Thousand USD | 220.82% |
| 2022 Q3 | -269 Thousand USD | -36.55% |
| 2022 FY | - USD | 84.54% |
| 2022 Q2 | -197 Thousand USD | 80.5% |
| 2022 Q1 | -1.01 Million USD | 62.0% |
| 2021 Q4 | -2.65 Million USD | -676.57% |
| 2021 Q1 | -757 Thousand USD | -7.07% |
| 2021 Q2 | -530 Thousand USD | 29.99% |
| 2021 FY | - USD | -130.05% |
| 2021 Q3 | 461 Thousand USD | 186.98% |
| 2020 Q1 | -534 Thousand USD | -184.36% |
| 2020 FY | - USD | -304.85% |
| 2020 Q4 | -707 Thousand USD | -553.21% |
| 2020 Q3 | 156 Thousand USD | 134.74% |
| 2020 Q2 | -449 Thousand USD | 15.92% |
| 2019 Q3 | 879 Thousand USD | 154.7% |
| 2019 Q2 | -1.6 Million USD | -828.9% |
| 2019 Q4 | 633 Thousand USD | -27.99% |
| 2019 Q1 | -173 Thousand USD | 93.74% |
| 2019 FY | - USD | 94.03% |
| 2018 Q3 | 1.03 Million USD | 1742.86% |
| 2018 Q2 | 56 Thousand USD | -93.64% |
| 2018 Q1 | 881 Thousand USD | 207.44% |
| 2018 Q4 | -2.76 Million USD | -367.64% |
| 2018 FY | - USD | -168.5% |
| 2017 FY | - USD | -94.08% |
| 2017 Q4 | -820 Thousand USD | -356.25% |
| 2017 Q3 | 320 Thousand USD | 173.39% |
| 2017 Q1 | -310 Thousand USD | -166.1% |
| 2017 Q2 | -436 Thousand USD | -40.65% |
| 2016 FY | - USD | -129.26% |
| 2016 Q2 | -465 Thousand USD | 19.13% |
| 2016 Q3 | -285 Thousand USD | 38.71% |
| 2016 Q1 | -575 Thousand USD | 25.42% |
| 2016 Q4 | 469 Thousand USD | 264.56% |
| 2015 Q2 | -479 Thousand USD | -29.11% |
| 2015 Q4 | -771 Thousand USD | -100.26% |
| 2015 FY | - USD | 79.53% |
| 2015 Q1 | -371 Thousand USD | -445.59% |
| 2015 Q3 | -385 Thousand USD | 19.62% |
| 2014 Q3 | -481 Thousand USD | 13.8% |
| 2014 FY | - USD | -866.84% |
| 2014 Q4 | -68 Thousand USD | 85.86% |
| 2014 Q1 | -731 Thousand USD | -175.85% |
| 2014 Q2 | -558 Thousand USD | 23.67% |
| 2013 FY | - USD | 94.99% |
| 2013 Q4 | -265 Thousand USD | -150.0% |
| 2013 Q3 | 530 Thousand USD | 145.61% |
| 2013 Q2 | -1.16 Million USD | -14.6% |
| 2013 Q1 | -1.01 Million USD | -206.85% |
| 2012 Q4 | 949 Thousand USD | 160.72% |
| 2012 Q1 | -400 Thousand USD | -65.98% |
| 2012 Q2 | -548 Thousand USD | -37.0% |
| 2012 Q3 | -1.56 Million USD | -185.22% |
| 2012 FY | - USD | -257.1% |
| 2011 Q4 | -241 Thousand USD | 15.73% |
| 2011 FY | - USD | 12.29% |
| 2011 Q3 | -286 Thousand USD | -5.93% |
| 2011 Q2 | -270 Thousand USD | 12.62% |
| 2011 Q1 | -309 Thousand USD | -2.32% |
| 2010 Q4 | -302 Thousand USD | -5.59% |
| 2010 FY | - USD | -146.9% |
| 2010 Q2 | -314 Thousand USD | 5.42% |
| 2010 Q1 | -332 Thousand USD | -7.79% |
| 2010 Q3 | -286 Thousand USD | 8.92% |
| 2009 Q3 | 17 Thousand USD | 101.41% |
| 2009 Q2 | -1.2 Million USD | -172.7% |
| 2009 FY | - USD | 127.98% |
| 2009 Q1 | 1.66 Million USD | 136.22% |
| 2009 Q4 | -308 Thousand USD | -1911.76% |
| 2008 Q1 | 1.97 Million USD | 107.39% |
| 2008 Q2 | -3.63 Million USD | -284.26% |
| 2008 FY | - USD | 63.86% |
| 2008 Q3 | -1.2 Million USD | 66.94% |
| 2008 Q4 | 704 Thousand USD | 158.67% |
| 2007 Q2 | -7.6 Million USD | -6772.81% |
| 2007 Q3 | 226 Thousand USD | 102.97% |
| 2007 Q4 | -26.64 Million USD | -11888.5% |
| 2007 FY | - USD | -60.85% |
| 2007 Q1 | 114 Thousand USD | 100.7% |
| 2006 FY | - USD | -51.12% |
| 2006 Q4 | -16.38 Million USD | -14474.56% |
| 2006 Q2 | -3.75 Million USD | -3392.98% |
| 2006 Q1 | 114 Thousand USD | 100.74% |
| 2006 Q3 | 114 Thousand USD | 103.04% |
| 2005 Q1 | 1.3 Million USD | 106.73% |
| 2005 Q2 | -2.54 Million USD | -294.79% |
| 2005 Q3 | 295 Thousand USD | 111.61% |
| 2005 Q4 | -15.5 Million USD | -5354.24% |
| 2005 FY | - USD | 36.12% |
| 2004 Q3 | 864 Thousand USD | 117.1% |
| 2004 Q4 | -19.36 Million USD | -2341.67% |
| 2004 Q2 | -5.05 Million USD | -684.95% |
| 2004 Q1 | 864 Thousand USD | 0.0% |
| 2004 FY | - USD | -207.17% |
| 2003 FY | - USD | 186.71% |
| 2002 FY | - USD | -17.11% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Matricelf Ltd | -11.51 Million ILA | 93.363% |